Went public 8/3/2000 at $11 per share
Filing Range: 4.6 mil. shares @ $11 to $13
Shares Outstanding: 22 mil. shares
Underwriters: Lehman Brothers/ Chase H&Q/Pacific Growth Equities
Company Counsel: O’Melveny & Myers
Manager Counsel: Dewey Ballantine LLP
Auditor: Pricewaterhouse Coopers LLP
Develops infectious disease therapeutic drugs which combine functional genomics, combinatorial chemistry, high throughput screening and informatics to identify novel agents. The company developed proprietary technology, called Gene-to-Screen, that allows the validation of any target genes essentiality and the creation of selectively hypersusceptible screening strains in a single step. This technology also allows the verification of the mechanism of action of a drug inside a cell providing an important support tool to the chemistry programs. In addition to its drug discovery activities the company intends to develop and sell drugs for the treatment of serious systemic microbial infections in the North American hospital market.
Patricof & Co. Ventures Inc.
Healthcare Ventures LLC
New Enterprise Associates
Abingworth Management Ltd.
Hambrecht & Quist
Schroder Ventures International Life Sciences
S.R. One Ltd.
Smith Kline Beecham Corp.
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 12/01/1997 7 Expansion 22000.0
2 12/09/1997 1 Expansion 9530.0
3 03/01/1999 2 Expansion 3750.0
4 03/01/1999 1 Expansion 3000.0
5 11/10/1999 11 Expansion 40180.2
(Data in $ millions)
Total Revenues: $4.3
Net Income: -25.1